Latest News
Feature
Drug price increases far outpaced inflation in 2015
Average increase in the cost of “market basket” of drugs widely used by older Americans has exceeded the inflation rate every year since 2004.
Conference Coverage
Unplanned cesareans more common with excess gestational weight gain
Almost half of women surveyed gained excess weight during pregnancy.
News
Pertuzumab approved for HER2-positive breast cancer
After a median follow-up period of 45.4 months, an invasive disease event occurred in 7.1% of all patients who received pertuzumab (Perjeta) and...
Conference Coverage
Axillary node dissection can be avoided with limited SLN involvement
SAN ANTONIO – Long-term follow-up confirms findings at 5 years, that DFS was similar for cohorts randomized to AD or no AD.
Conference Coverage
ERBB2 expression predicts pCR in HER2+ breast cancer
In the phase 3 NeoALTTO trial, the amplification of ERBB2 was shown to be predictive of pCR; its expression was more predictive of pCR.
Feature
HealthCare.gov enrollment for 2018 nearly doubled in final week
Plans selected this year were down slightly from last year’s much longer open-enrollment period.
Conference Coverage
Contraceptive use appears low in teen girls on teratogenic medications
SAN DIEGO – Study finds 7.6% became pregnant over a 3-year period, and only 25% of those had filled birth control prescriptions.
Conference Coverage
DCIS risk signature is validated in SweDCIS population
SAN ANTONIO – The biologic risk signature was not only prognostic, but also predictive for radiotherapy benefit.
Conference Coverage
Path CR signals good outcomes in treated high-risk breast cancers
In I-SPY 2, regardless of tumor type, a pCR following chemotherapy and surgery predicted better outcomes in patients with stage 2 or 3 breast...
News
FDA: Laparoscopic power morcellators can spread malignant cells when used in women with occult uterine cancers*
The findings reinforce the FDA’s warnings that these devices shouldn’t be used to remove fibroids from some women.
From the Journals
Self-administered subcutaneous Depo-Provera ‘feasible and acceptable’
Self-injected contraception “has potential to reduce barriers and disparities in access,” wrote Dr. Julia E. Kohn.